Not a "drug safety-testing lab" — compliance validation infrastructure. GLP is the only node that connects both drug compliance (ICH) and device compliance (ISO 10993), making it the hub for the entire chain.
GLP safety evaluation is carried out at the Yangtze River Delta National Innovation Centre for Drug Safety Evaluation Technology. The platform operates within that national innovation system rather than as an outside client of it, and handles study design, organoid pre-screening and submission coordination.
Organoid technology serves as a front-end pre-screening tool for GLP, filtering out ineffective candidate molecules before formal animal testing begins — significantly lowering failure rates and costs, while also supplying mechanistic data that supports GLP reports.
GLP safety evaluation is carried out at an established national evaluation centre inside our own system.
The in-system centre that carries out the platform’s GLP safety evaluation work is led by Prof. Liao Mingyang. His positions and recognitions are held at national evaluation and regulatory bodies:
What this means for your project: the GLP report supporting your submission is issued by an established national evaluation centre within our own system — you are not being handed off to a third-party lab. The platform handles study design, organoid pre-screening ahead of the GLP phase, and submission coordination.